GlassScriptPhysician profile
Jie Pan
NPI 1609369990
$4,845.48
in general payments reported to CMS, 2019-2025
32 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $31.44 · 2021: $549 · 2022: $87.96 · 2023: $523 · 2024: $1,443 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $684.98 | 2023-2025 | |
| Abbvie INC. | $500.61 | 2021-2025 | |
| Ucb, INC. | $355.77 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Acadia Pharmaceuticals INC | $326.32 | 2023-2025 | Nuplazid |
| Genzyme Corporation | $301.62 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $290.54 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $269.28 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $216.68 | 2021-2025 | Leqembi, Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $181.56 | 2019-2025 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $178.47 | 2023-2025 | Amvuttra |
| Mdd US Operations, LLC | $164.08 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Csl Behring | $160.07 | 2023-2025 | Hizentra |
| Emd Serono, INC. | $159.11 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $126.36 | 2022-2025 | |
| Lundbeck LLC | $120.93 | 2022-2025 | Vyepti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $113.64 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $113.20 | 2021 | |
| Scilex Pharmaceuticals INC. | $82.36 | 2024-2025 | |
| Janssen Biotech, INC. | $82.33 | 2025 | |
| Amneal Pharmaceuticals LLC | $81.62 | 2023-2025 | Crexont, Rytary |
| Livanova USA, INC. | $64.11 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $59.13 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Otsuka America Pharmaceutical, INC. | $34.70 | 2024-2025 | Nuedexta, Rexulti |
| Abbott Laboratories | $24.29 | 2025 | Infinity |
| Amgen INC. | $23.16 | 2024 | Uplizna |
| Pfizer INC. | $21.83 | 2025 | |
| Neurelis, INC. | $20.04 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $19.77 | 2025 | Wainua |
| Tanabe Pharma America, INC. | $19.22 | 2025 | Radicava |
| Celgene Corporation | $18.01 | 2020 | |
| Axsome Therapeutics, INC. | $16.69 | 2025 | Symbravo |
| Averitas Pharma INC. | $15.00 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.